Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations

Wang, H-YH-YWangSHANG-GIN WUYEN-TING LINCHUNG-YU CHENJIN-YUAN SHIH2022-12-202022-12-202022-12-0620597029https://scholars.lib.ntu.edu.tw/handle/123456789/626636Anaplastic lymphoma kinase-positive (ALK+) and ROS proto-oncogene 1 (ROS1)-positive (ROS1+) lung cancers have been reported to be associated with an elevated risk of thromboembolic events. This study aimed to assess the long-term risk of developing thromboembolism (TE) in ROS1+ lung cancer and to compare it with other oncogenic drivers in the Asian population.enALK; EGFR; ROS1 rearrangement; non-small-cell lung cancer; thromboembolism[SDGs]SDG3Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutationsjournal article10.1016/j.esmoop.2022.100742364936002-s2.0-85143872660https://api.elsevier.com/content/abstract/scopus_id/85143872660